79885-37-3 Usage
Uses
Used in Pharmaceutical Research:
6-BROMO-2(1H)-QUINAZOLINONE is used as a building block in organic synthesis for its potential therapeutic applications, particularly in the treatment of neurological disorders and cancer. Its unique structure allows it to be a key component in the development of new pharmaceuticals.
Used in Antimicrobial Applications:
6-BROMO-2(1H)-QUINAZOLINONE is used as an antimicrobial agent due to its potential to combat various types of infections. Its ability to inhibit the growth of bacteria makes it a candidate for further research in this field.
Used in Antifungal Applications:
Similarly, 6-BROMO-2(1H)-QUINAZOLINONE is used as an antifungal agent, indicating its potential to treat fungal infections. Its effectiveness against fungi is an area of interest for researchers looking to develop new antifungal medications.
Check Digit Verification of cas no
The CAS Registry Mumber 79885-37-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,9,8,8 and 5 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 79885-37:
(7*7)+(6*9)+(5*8)+(4*8)+(3*5)+(2*3)+(1*7)=203
203 % 10 = 3
So 79885-37-3 is a valid CAS Registry Number.
InChI:InChI=1/C8H5BrN2O/c9-6-1-2-7-5(3-6)4-10-8(12)11-7/h1-4H,(H,10,11,12)
79885-37-3Relevant academic research and scientific papers
Inhibitors of the fibroblast growth factor receptor
-
Page/Page column 38, (2017/08/01)
Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.
INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
-
Paragraph 0129; 0130, (2015/07/22)
Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.
INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
-
Page/Page column 37; 38, (2014/02/15)
Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.
